Aurinia Pharmaceuticals
AUPH
61 hedge funds and large institutions have $151M invested in Aurinia Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 9 closing their positions.
6% more capital invested
Capital invested by funds: $143M → $151M (+$8.92M)
0.85% more ownership
Funds ownership: 25.18% → 26.04% (+0.85%)
3% less funds holding
Funds holding: 63 → 61 (-2)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
62% less call options, than puts
Call options by funds: $896K | Put options by funds: $2.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$2.89M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.13M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$819K |
| 4 |
D.E. Shaw & Co
New York
|
+$720K |
| 5 |
Rockefeller Capital Management
New York
|
+$528K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$697K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$517K |
| 3 |
Goldman Sachs
New York
|
-$465K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$389K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$365K |
AUPH Hedge Fund Activity: Q4 2018 in Review
61 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2018, worth a combined $151M — up 6.3% from $143M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AUPH and 7 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 17 added.
The largest buyer was Polar Capital, adding an estimated $2.89M. The largest seller was UBS Group, cutting an estimated $697K.
- 61 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2018, down from 63 in Q3 2018.
- Funds reported $151M of Aurinia Pharmaceuticals stock for Q4 2018, up 6.3% quarter-over-quarter.
- 7 funds opened new Aurinia Pharmaceuticals positions in Q4 2018 and 9 closed out, a net change of -2 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2018 was Polar Capital, an estimated $2.89M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2018 was UBS Group, an estimated $697K sold.
Based on aggregated 13F filings for Q4 2018.